Nikki K. Lytle

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Mohammed Aldakkak · 4 shared papers, 2026 · strength 0.86
   • Paper Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. DOI 10.1016/j.jcmgh.2026.101872↗
   • Paper AI-Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2026.0291↗
   • Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
2. Mandana Kamgar · 3 shared papers, 2026 · strength 0.64
   • Paper AI-Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2026.0291↗
   • Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
   • Paper Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-1181↗
3. Laura DeLong Wood · 1 shared paper, 2026 · strength 0.63
   • Paper The want for Wnt: Pancreatic cancer assembles a self-sustaining Wnt-signaling ecosystem. DOI 10.1016/j.devcel.2026.04.010↗
4. Susan Tsai · 3 shared papers, 2023–2026 · strength 0.55
   • Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
   • Paper Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-1181↗
   • Paper Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer. DOI 10.1016/j.ccell.2023.09.008↗
5. Andrew M. Lowy · 6 shared papers, 2016–2023 · strength 0.52
   • Paper Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-023-35796-7↗
   • Paper Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer. DOI 10.1016/j.ccell.2023.09.008↗
   • Paper Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-021-04176-w↗
6. Tannishtha Reya · 6 shared papers, 2016–2023 · strength 0.52
   • Paper Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-023-35796-7↗
   • Paper Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer. DOI 10.1016/j.ccell.2023.09.008↗
   • Paper Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-021-04176-w↗
7. William Adrian Hall · 2 shared papers, 2026 · strength 0.43
   • Paper AI-Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2026.0291↗
   • Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
8. Sam Z. Thalji · 2 shared papers, 2026 · strength 0.43
   • Paper AI-Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2026.0291↗
   • Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
9. Beth E. Erickson · 2 shared papers, 2026 · strength 0.43
   • Paper AI-Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2026.0291↗
   • Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
10. Kathleen K. Christians · 2 shared papers, 2026 · strength 0.43
    • Paper AI-Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2026.0291↗
    • Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
11. Yongwoo David Seo · 2 shared papers, 2026 · strength 0.41
    • Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
    • Paper Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-1181↗
12. Daniel Dorbin · 2 shared papers, 2026 · strength 0.41
    • Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
    • Paper Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-1181↗
13. Douglas B. Evans · 2 shared papers, 2026 · strength 0.41
    • Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
    • Paper Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-1181↗
14. Thomas B. McFall · 2 shared papers, 2026 · strength 0.41
    • Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
    • Paper Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-1181↗
15. G. Aaron Hobbs · 2 shared papers, 2026 · strength 0.41
    • Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
    • Paper Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-1181↗
16. Razelle Kurzrock · 2 shared papers, 2026 · strength 0.41
    • Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018↗
    • Paper Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-1181↗
17. Daniel D. Von Hoff · 4 shared papers, 2019–2023 · strength 0.34
    • Paper Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer. DOI 10.1016/j.ccell.2023.09.008↗
    • Paper Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. DOI 10.1038/s41586-021-04176-w↗
    • Paper A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma. DOI 10.1016/j.cell.2019.03.010↗
18. Lesley Paige Ferguson · 3 shared papers, 2019–2023 · strength 0.33
    • Paper Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-023-35796-7↗
    • Paper Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer. DOI 10.1016/j.ccell.2023.09.008↗
    • Paper A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma. DOI 10.1016/j.cell.2019.03.010↗
19. Nirakar Rajbhandari · 3 shared papers, 2019–2023 · strength 0.33
    • Paper Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-023-35796-7↗
    • Paper Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer. DOI 10.1016/j.ccell.2023.09.008↗
    • Paper A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma. DOI 10.1016/j.cell.2019.03.010↗
20. Raymond G. Fox · 3 shared papers, 2016–2023 · strength 0.24
    • Paper Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer. DOI 10.1016/j.ccell.2023.09.008↗
    • Paper A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma. DOI 10.1016/j.cell.2019.03.010↗
    • Paper Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. DOI 10.1038/nature17988↗
21. Oliver Gene McDonald · 1 shared paper, 2026 · strength 0.23
    • Paper Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. DOI 10.1016/j.jcmgh.2026.101872↗
22. Christopher J. Halbrook · 1 shared paper, 2026 · strength 0.23
    • Paper Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. DOI 10.1016/j.jcmgh.2026.101872↗
23. Nina G. Steele · 1 shared paper, 2026 · strength 0.23
    • Paper Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. DOI 10.1016/j.jcmgh.2026.101872↗
24. Austin D. Silva · 1 shared paper, 2026 · strength 0.23
    • Paper Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. DOI 10.1016/j.jcmgh.2026.101872↗
25. David K. Imagawa · 1 shared paper, 2026 · strength 0.23
    • Paper Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. DOI 10.1016/j.jcmgh.2026.101872↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.